Display options
Cite
Habib FK, Ross M, Bayne CW, et al. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin Cancer Res. 2003;9(5):1815-9
Habib, F. K., Ross, M., Bayne, C. W., Bollina, P., Grigor, K., & Chapman, K. (2003). The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research, 9(5), 1815-9.
Habib, Fouad K, et al. "The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 9,5 (2003): 1815-9.
Habib FK, Ross M, Bayne CW, Bollina P, Grigor K, Chapman K. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis. Clin Cancer Res. 2003 May;9(5):1815-9. PMID: 12738739.
Copy Download .nbib Format: NLM
Share it on

Clin Cancer Res. 2003 May;9(5):1815-9.

The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.

Clinical cancer research : an official journal of the American Association for Cancer Research

Fouad K Habib, Margaret Ross, Colin W Bayne, Prasad Bollina, Ken Grigor, Karen Chapman

Affiliations

  1. Prostate Research Group, University Department of Oncology, Western General Hospital, Edinburgh, Scotland EH4 2XU, United Kingdom. [email protected]

PMID: 12738739

Abstract

PURPOSE: Considerable evidence has accumulated demonstrating that the 5alpha-reduction of testosterone to dihydrotestosterone occurs more efficiently in the normal and benign hyperplastic prostate than in prostate cancer tissues. Efforts have also been channeled into investigating the distribution of 5alpha-reductase isoenzymes in primary prostate tissues and in "in vitro" cell models of the human prostate. However, no one has, thus far, examined the expression of these isoenzymes in prostate cancer metastasis, although such studies might shed some light on the mechanism(s) responsible for the loss of hormone sensitivity in those tumors. The present report addresses this issue in the hope that this might help to identify the steps leading to the development of prostate cancer metastasis.

EXPERIMENTAL DESIGN: In the present study we used in situ mRNA hybridization of sections from archival paraffin-embedded material to investigate the expression of 5alpha-reductase type I (5alphaR-I) and type II (5alphaR-II) mRNAs in prostate cancer bony (n = 9) and lymph node (n = 13) metastasis, and compared the mRNA distributions with those observed in sections from primary prostate tumors (n = 12). In parallel, sections were investigated for androgen receptor (AR) mRNA expression, and immunostained for AR and prostate-specific antigen.

RESULTS: Neither 5alphaR-I nor 5alphaR-II mRNA expression was detected in any of the prostate metastatic lesions, although the same metastatic sites expressed AR mRNA, and stained for cytoplasmic prostate-specific antigen and nuclear AR. In contrast, primary prostate tumors displayed intense staining for 5alphaR-I and 5alphaR-II.

CONCLUSION: These findings suggest that the loss of 5alpha-reductase mRNA expression in bone and lymph node metastasis may be associated, in part, with the progression of these tumors to androgen insensitivity.

Substances

MeSH terms

Publication Types